Clinical Trials Logo

Filter by:
NCT ID: NCT02342249 Completed - Influenza A Clinical Trials

Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects

Start date: December 11, 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the antiviral effect, as measured by viral titer in nasal secretions in adults with acute uncomplicated seasonal influenza A following administration of VX-787.

NCT ID: NCT02341885 Completed - Acute Kidney Injury Clinical Trials

PrEvalence of Acute and Chronic Kidney Disease Treated by Renal Replacement Therapy

PEACE
Start date: March 2015
Phase: N/A
Study type: Observational

A prospective international, multi-centre, prevalence study on the epidemiology of the use of renal replacement therapy for ICU patients who have acute kidney injury and chronic end stage kidney disease.

NCT ID: NCT02341729 Completed - Clinical trials for Acute Coronary Syndrome

Effects and Plasma Concentration of Ticagrelor, After Crushed and Non-crushed Intake, After Acute Coronary Syndrome

ticagrelor
Start date: March 2015
Phase: Phase 4
Study type: Interventional

The first aim of the study is to prove that after starting the therapy with crushed tablets, the platelet inhibition will be as expected after starting therapy with intact tablets. Gurbel et al. showed that 100% of the patients on ticagrelor treatment have a decrease from baseline platelet aggregation of >10% 4 hours after last maintenance dose. So the investigators expect that after 3 days of treatment, all of our patients will have a closing time of more than 106seconds. The investigators will observe two different clinical conditions of Acute Coronary Syndrome. First after semi-urgent coronary artery bypass graft (CABG) surgery, secondly in patients after cardiac arrest. Both are clinical situations in which crushed tablets are needed to give. The second objective is to determine plasma concentrations of Ticagrelor and AR-C124910XX (active metabolite of ticagrelor) in these two patient populations after receiving 180mg or 90mg start-dose. Determination of plasma concentrations is done after protein precipitation, by using liquid chromatography with mass spectrometry detection. Measurements will be determined before intake (0h) and at 0,5; 1; 2; 4; 8; 24h and at day 4 +4h.7 The first 24h this will be a crushed tablet and 4 hours after the first intake at day 4 of therapy, this will be a non crushed tablet.

NCT ID: NCT02341534 Completed - Clinical trials for Myocardial Infarction

BIO monitorinG in Patients With Preserved Left ventricUlar Function AfteR Diagnosed Myocardial Infarction

BIO-GUARD-MI
Start date: August 7, 2015
Phase: N/A
Study type: Interventional

The BIO|GUARD-MI study investigates whether continuous arrhythmia monitoring and the consequent treatment after detected arrhythmias in patients after myocardial infarction with preserved cardiac function, but other risk factors, decreases the risk of major adverse cardiac events.

NCT ID: NCT02341417 Completed - Clinical trials for Secondary Hyperparathyroidism, Chronic Kidney Disease

Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on Dialysis

Start date: June 10, 2015
Phase: Phase 3
Study type: Interventional

The primary objective of this study was to characterize the long-term safety and tolerability of cinacalcet in pediatric patients with chronic kidney disease (CKD) receiving dialysis.

NCT ID: NCT02339688 Completed - Multiple Sclerosis Clinical Trials

Psychometric Properties Mobility Measures MS

MCS-III-MOB
Start date: October 2014
Phase: N/A
Study type: Interventional

Current study will investigate the quality (psychometric properties) and clinical utility of several mobility measures, according to disability level. Therefore, several aspects will be inquired: - Was there an effect of rehabilitation - Is the measure able to detect change over time? And thus the change exceed measurement error and is it clinically important (responsiveness) - Does the measure assess what it claims to measure (validity) - Is the measure able to differentiate all performances of the patients, inclusively the very good and very bad performances (floor and ceiling effects) - Does the measure gives similar results under consistent test conditions on another testing day (reliability) Worldwide, theoretical approaches to physical therapy and rehabilitation in Multiple Sclerosis often appear significantly different. Since the present research protocol will be performed at different centers across European countries (and US sites), this multi-center study can additionally be applied for mapping the volume and content of rehabilitation, as well as the differential impact of diverse rehabilitation approaches and training volume on mobility, for several disability levels. Some health-economic analyses will be performed to examine what the approximate cost of rehabilitation compared to effects is and what drivers of costs are (setting, equipment, staff).

NCT ID: NCT02339675 Completed - Multiple Sclerosis Clinical Trials

Psychometric Properties Upper Limb Function Measures Multiple Sclerosis

MCS-III-UL
Start date: October 2014
Phase: N/A
Study type: Interventional

Current study will investigate de quality (psychometric properties) and clinical utility of several measures of upper limb function, according to disability level. Therefore, several aspects will be inquired: - Was there an effect of rehabilitation - Is the measure able to detect change over time? And thus the change exceed measurement error and is it clinically important (responsiveness) - Does the measure assess what it claims to measure (validity) - Is the measure able to differentiate all performances of the patients, inclusively the very good and very bad performances (floor and ceiling effects) - Does the measure gives similar results under consistent test conditions on another testing day (reliability) Worldwide, theoretical approaches to physical therapy and rehabilitation in Multiple Sclerosis often appear significantly different. Since the present research protocol will be performed at different centers across European countries (and US sites), this multi-center study can additionally be applied for mapping the volume and content of rehabilitation, as well as the differential impact of diverse rehabilitation approaches and training volume on mobility, for several disability levels. Some health-economic analyses will be performed to examine what the approximate cost of rehabilitation compared to effects is and what drivers of costs are (setting, equipment, staff).

NCT ID: NCT02338843 Completed - Sepsis Clinical Trials

A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension

ATHOS-3
Start date: March 2015
Phase: Phase 3
Study type: Interventional

This is a Phase 3, double-blind, randomized study of LJPC-501 (angiotensin II) in adult patients diagnosed with catecholamine-resistant hypotension (CRH) conducted in multiple centers globally.

NCT ID: NCT02338609 Completed - Clinical trials for Growth and Development

Long-term Follow-up for Growth and Development of Pediatric Patients From CRAD001M2301

EXIST-LT
Start date: December 17, 2014
Phase: Phase 4
Study type: Interventional

The primary objective of CRAD001M2305 is to report the long-term effects of everolimus treatment on height, weight and sexual development (using Tanner Stages) in children and adolescents with Tuberous Sclerosis Complex (TSC)-associated with Subependymal Giant Cell Astrocytoma (SEGA). The study will monitor the growth and development of pediatric patients with TSC-associated SEGA, previously enrolled in CRAD001M2301 until they reach Tanner Stage V, or until age 16 for females or 17 for males whichever occurs first.

NCT ID: NCT02337907 Completed - Alzheimer Disease Clinical Trials

BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.

Start date: January 21, 2015
Phase: Phase 2
Study type: Interventional

The study is designed to compare the effects of BI 409306 compared to placebo in patients with cognitive impairment due to Alzheimer's Disease